I'm going to put this in the very small Good News Column
President Bill Clinton and his foundation have brokered a landmark deal to provide a new HIV prevention drug, lenacapavir, at a dramatically lower cost for low- and middle-income countries. This agreement, which could help millions access the breakthrough treatment, is a step toward ending the HIV epidemic
Key details of the announcement:
•The drug: Lenacapavir is a groundbreaking HIV prevention drug that is administered as an injection twice a year.
•Reduced price: The deal, negotiated by the Clinton Foundation and partners like the Gates Foundation, will lower the price of lenacapavir to just $40 per patient annually for 120 countries. This is a significant reduction from its previous annual cost of over $28,000 in the U.S..
•Availability: Generic versions of the drug are expected to roll out starting in 2027.
•Partnership: The agreement was reached in partnership with the Clinton Health Access Initiative (CHAI) and other organizations, including the Gates Foundation, Wits RHI, and generic drug manufacturers.
Clinton and his foundation have a long history of negotiating lower prices for HIV/AIDS medications for developing nations.